{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-010640","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.343499+00:00","generated_at":"2026-05-17T17:32:35.509854+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aclaris Q2 net loss widens to $15.4M; advances ATI-2138, bosakitug, ATI-052 trials","bullets":["Net loss $15.4M vs $11.0M YoY; revenue $1.8M, down 36% due to prior royalty sale.","Cash, equivalents & securities $180.9M; runway into H2 2028 without new financing.","Phase 2a ATI-2138 met primary/key secondary endpoints; confirms tolerability in moderate-to-severe AD.","Phase 2 trial of bosakitug (anti-TSLP mAb) in AD dosing; top line expected H2 2026.","Roland Kolbeck appointed CSO replacing Joe Monahan (planned retirement through Q1 2026)."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-010640","json":"https://secwatch.observer/filing/0001558370-25-010640.json","markdown":"https://secwatch.observer/filing/0001558370-25-010640.md","text":"https://secwatch.observer/filing/0001558370-25-010640.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000155837025010640/0001558370-25-010640-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000155837025010640/acrs-20250807x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:32:35.509854+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}